Abstract: Oxidative stress is a damaging process resulting from an imbalance between excessive generation of oxidant compounds and insufficient antioxidant defence mechanisms. Oxidative stress plays a crucial role in the initiation and progression of cigarette smoke-induced lung injury, deterioration in lung functions, and development of chronic obstructive pulmonary disease (COPD). In smokers and in patients with COPD, the increased oxidant burden derives from cigarette smoke per se, and from activated inflammatory cells releasing enhanced amounts of reactive oxygen and nitrogen species (ROS, RNS, respectively). Although mild oxidative stress resulting from cigarette smoking leads to the upregulation of the antioxidative enzymes synthesis in the lungs, high levels of ROS and RNS observed in patients with COPD overwhelm the antioxidant enzymes capacities, resulting in oxidant-mediated lung injury and cell death. In addition, depletion of antioxidative systems in the systemic circulation was consistently observed in such patients. The imbalance between the generation of ROS/RNS and antioxidant capacities -the state of "oxidative stress" -is one of the major pathophysiologic hallmarks in the development of COPD. Detrimental effects of oxidative stress include impairment of membrane functions, inactivation of membrane-bound receptors and enzymes, and increased tissue permeability. In addition, oxidative stress aggravates the inflammatory processes in the lungs, and contributes to the worsening of the protease-antiprotease imbalance. Several markers of oxidative stress, such as increases in lipid peroxidation products and reductions in glutathione peroxidase activity, have been shown to be related to the reductions in pulmonary functions. In the present article we review the current knowledge about the vicious cycle of cigarette smoking, oxidative stress, and inflammation in the pathogenesis of COPD.
Introduction
Numerous studies have revealed that oxidative stress plays a crucial role in the initiation and progression of a wide range of diseases, and in the regulation of a number of important biological processes. Pulmonary diseases associated with oxidative stress include chronic obstructive pulmonary disease (COPD), bronchial asthma, hyperoxia, sarcoidosis, and chronic berrylium disease (Comhair & Erzurum, 2002) . COPD is the fifth most prevalent disease worldwide, and the World Health Organization predicts that by 2020 COPD will be the 3 rd most common cause of death (Lopez & Murray, 1998) .
In the ethiology of COPD, cigarette smoking is the strongest risk factor, accounting for the disease progression in 85-90% of patients (Bach et al., 2001) . The increased oxidant burden in patients with COPD resulting from cigarette smoke per se and from the activation of inflammatory cells in the airspaces is not adequately counterbalanced by the antioxidant systems, resulting in oxidative stress (Drost et al., 2005) . In addition, oxidative stress aggravates further the inflammatory processes in the lungs. The aim of the present article is to review the current knowledge about the role of oxidative stress in the smoking-induced lung injury, particularly in patients with COPD.
Oxidants
More than 90% of patients with COPD are smokers, however, COPD develops in only about 20% of those who smoke. The increased oxidant burden in smokers derives from the fact that cigarette smoke contains more than 10 14 free radicals/oxidants per puff, and is a complex mixture of over 4,700 chemical compounds (Pryor & Stone, 1993) . The lung is also exposed to endogenous oxidants, which presumably summate with exogenous oxidant production to further enhance oxidative stress in the lungs (Domej et al., 2006) .
ROS, RNS and NO
The major oxidants in the airways are reactive oxygen and reactive nitrogen species (ROS, RNS, respectively). ROS include superoxide anion, hydrogene peroxide and hydroxyl radical. Superoxide anions (O .− 2 ) are converted to hydrogen peroxide (H 2 O 2 ) by superoxide dismutases (SODs). H 2 O 2 is then dismuted to water by catalase (CAT). O .− 2 and H 2 O 2 may interact in the presence of free iron to form the highly reactive hydroxyl radical ( . OH) (Fig. 1.) .
RNS are primarily derived from nitric oxide. NO is considered a signalling molecule with vasodilatatory, bronchodilatatory, and immunomodulatory properties (Montuschi et al., 2001) . The sources of NO are three NO synthases (NOS): constitutive (cNOS), inducible (iNOS) and neuronal (nNOS). Only iNOS, which is found in respiratory epithelium and activated macrophages, is highly upregulated by inflammatory cytokines, such as tumour necrosis factor-α (TNF-α) (Bowler et al., 2002) . iNOS expression is induced under inflammatory and oxidant conditions, such as COPD (Ichinose et al., 2000; Biernacki et al., 2003; Maestrelli et al., 2003) . NO is the most extensively studied exhaled marker of airway inflammation and oxidative stress. Increased exhaled NO levels were observed in ex-smokers with COPD compared to healthy non-smokers, and in current smokers with COPD compared to healthy current smokers (Corradi et al., 1999; Montuschi et al., 2001) . Moreover, exhaled NO is increased during COPD exacerbations compared with stable COPD (Maziak et al., 1998) . In addition, RNS such as nitrotyrosine and nitrothiol can cause damage to the lung. Peroxynitrite causes nitrosylation of tyrosine to produce nitrotyrosine. Importantly, nitrotyrosine and nitrothiol levels were shown to be elevated in patients with COPD, and correlate negatively with obstructive lung impairment (Manney et al., 2004) .
Lipid peroxidation
Other mechanisms by which the oxidants can cause lung injury include lipid peroxidation, oxidative damage to proteins with subsequent increased susceptibility to proteolytic degradation, and oxidative damage to DNA. Lipid peroxidation of polyunsaturated membrane fatty acids results from activated ROS released by immune and inflammatory cells. The detrimental consequences of membrane lipid peroxidation involve impairment of membrane function, inactivation of membranebound receptors and enzymes, and increased tissue permeability (Paredi et al., 2000) . The most widely used marker of lipid peroxidation is malondialdehyde (MDA). MDA is a highly toxic molecule with detrimental effects on the cell structures through its ability to react with molecules such as DNA and proteins (Del Rio et al., 2005) . Voitkun & Zhintovich (1999) reported on potentially genotoxic and cancerogenic properties of MDA. Moreover, MDA toxicity towards endothelium through generating products that have been detected in fractions of oxidized lipoproteins involved in atherogenesis has been described (Uchida, 2000) . Increases in MDA have been observed in several disease conditions, such as diabetes (Dierckx et al., 2003) , breast cancer (Akbulut et al., 2003) or Alzheimer disease (Delibas et al., 2002) . In patients with COPD, increases in circulatory MDA were associated with the reductions of total antioxidant capacity in the blood (Tug et al., 2004) . In addition, MDA levels were significantly higher in COPD patients compared to healthy controls, and during acute exacerbation compared to stable state of the disease (Calikoglu et al., 2002) .
Ethane Ethane (hydrocarbon byproduct of lipid peroxidation) is another marker of lipid peroxidation that received particular attention because of its easier and faster chromatographic measurement compared with other hydrocarbons such as pentane. Chronic elevations of ethane in smokers are likely related to oxidative damage in the lungs as indicated by a highly significant correlation between ethane levels and the degree of airway obstruction in COPD (Paredi et al., 2000) .
Isoprostanes
Oxidative stress leads to the oxidation of arachidonic acid and to the formation of prostanoid mediators called isoprostanes (Morrow, 2000) that have important physiological consequences, such as bronchoconstriction and plasma exudation (Janssen, 2001) . Isoprostanes are prostaglandin-like compounds formed by free radical-catalyzed lipid peroxidation of arachidonic acid. In healthy cigarette smokers and, to a much greater extent, in patients with COPD, increases in breath and urinary concentrations of 8-isoprostane were observed (Montuschi et al., 2000) . Also, Musil et al. (2004) documented an association between airway obstruction and the concentrations of leukotrienes in exhaled breath condensate of patients with COPD.
Smoking-induced lung inflammation as a source of increased burden of oxidants COPD is a chronic inflammatory disease characterized by an increase in neutrophils, macrophages, and T lymphocytes (especially CD8 + ) in various parts of the lung (Barnes, 2000a) , which are driven by inflammatory mediators such as cytokines, chemokines, and oxidants . T lymphocytes, particularly CD8 + cells and macrophages, are the prevalent inflammatory cells in the lung of healthy smokers and patients with mild COPD, while total and activated neutrophils predominate in severe COPD (Di Stefano et al., 2004) .
Alveolar macrophages
Alveolar macrophages appear to have a prominent role in the inflammatory response in hypoxia-induced lung injury and the related upregulation of inflammatory mediators. Woodruff et al. (2005) observed that smoking induces a remarkably consistent and distinctive pattern of alveolar macrophage activation that may play an important role in the pathogenesis of COPD. Macrophages activated by cigarette smoke release proteolytic enzymes and neutrophil-chemotactic factors, such as leukotriene B4 and interleukin (IL)-8 (Pons et al., 2005) .
Cytotoxic T lymphocytes
Cytotoxic T lymphocytes (CD8 + ) have been related to the progressive reduction of pulmonary function in both COPD (Hogg, 2004) and asthma (van Rensen et al., 2005) . A low CD4 + /CD8 + ratio is a feature characteristic of the pulmonary inflammatory response in COPD. The significant correlation between the number of CD8 + cytotoxic T lymphocytes and the degree of airflow limitation in COPD suggests a role of these cells in the progression of COPD (Saetta et al., 1999) . Recent studies indicate that CD4
+ lymphocytes are also increased in COPD, particularly in severe cases (Hogg, 2004) . Severe emphysema is associated with apoptosis of alveolar epithelial cells (Calabrese et al., 2005) and inflammation involving T lymphocytes that are composed of oligoclonal CD4
+ lymphocytes (Sullivan et al., 2005) . These findings point to a possible immune mechanism of lung inflammation in COPD (Willemse et al., 2005) .
Neutrophils
The airways of smokers and patients with COPD are highly infiltrated with neutrophils (Confalonieri et al., 1998) . The lungs contain a large pool of noncirculating (marginated) neutrophils. The first step in the recruitment of neutrophils to the airspaces is the sequestration of these cells in the lung microcirculation. This occurs under normal circumstances in the pulmonary capillary bed, as a result of the size differential between neutrophils (average diameter, 7 µm) and pulmonary capillary segments (average diameter, 5 µm). Thus a proportion of the circulating neutrophils have to deform in order to negotiate the smaller capillary segments. Studies in man show a transient increase in neutrophil sequestration in the lungs during smoking (MacNee, 2001) , which returns to normal after cessation of smoking. Sivelestat, a highly specific neutrophil elastase inhibitor, preserves neutrophil deformability (Matsuzaki et al., 2005) , and reduces both neutrophil elastase levels and IL-8 production. Neutrophils have azurophilic granules containing elastase, cathepsin G and defensins, which are released at sites of inflammation. The mechanisms by which neutrophils degranulate are not completely understood. The neutrophil elastase is capable of degrading most components of the extracellular matrix, an event that is normally inhibited by antiproteinases such as α 1 -antitrypsin.
Bronchial epithelial and endothelial cells
Bronchial epithelial cells have the potential to synthesize and release a wide variety of inflammatory mediators, such as IL-8 or TNF-α. Cigarette smoke increases epithelial permeability both in vitro and in vivo. This increase in epithelial permeability is partly reversible by antioxidants and thus oxidant-mediated (Rusznak et al., 2000) . Also, epithelial cells are the main source of vascular endothelial growth factor (VEGF) that induces endothelial cell proliferation, and its withdrawal leads to endothelial cell apoptosis (Kasahara et al., 2001) and to epithelial cell injury (Thickett et al., 2002) . Kanazawa & Yoshikawa (2005) hypothesized that oxidative stress reflected by increases in peroxynitrite in pulmonary epithelial and endothelial cells is associated with increased apoptosis of epithelial cells in patients with COPD. It seems likely that the thin layer of epithelial lining fluid may provide antioxidant protection against peroxynitrite and may serve as a front-line defence for epithelial cells. Kasahara et al. (2001) doc-umented in resected COPD lung tissue specimen that although both epithelial and endothelial cells were undergoing apoptosis, the apoptotic cells were mainly epithelial cells, which in turn may have affected the endothelial cells via reduced production of their survival factor, VEGF (Tsao et al., 2004) . Indeed, the loss of VEGF potentiates epithelial cell injury mediated by oxidative stress in COPD (Tuder et al., 2003) . On the other hand, VEGF upregulates the antioxidative mitochondrial manganese superoxide dismutase (MnSOD) expression in vitro (Abid et al., 2001 ).
Nuclear factor-κB Oxidative stress may exacerbate COPD through several mechanisms, such as: (a) the activation of the transcription factor nuclear factor-κB (NF-κB); (b) neutrophil sequestration in the lungs; and (c) oxidative damage of antiproteases. These three mechanisms enhance inflammation and proteolytic injury to the lungs (Barnes, 2000b) . Recent studies indicate that oxidative stress is a biologically plausible cause of increased inflammation. Indeed, Drost et al. (2005) documented that markers of oxidative stress in bronchoalveolar lavage are markedly increased during severe exacerbations of the disease, in association with increased neutrophil influx and rises in IL-8 levels. Several data point to the key role of NF-κB in the activation of inflammatory processes by oxidative stress. NF-κB is an inducible transcription factor that is required for cell survival and immunity, however, its abnormal expression or activation leads to the development of many pathological states, especially those involved in chronic and acute inflammation (Aldonyte et al., 2003) . NF-κB is present in the cytosol in an inactive form linked to its inhibitory protein, and is being activated by stimuli like cytokines and oxidants (Li & Verma, 2002) . Jimenez et al. (2000) have shown in studies in vitro, using both macrophage cell lines and alveolar and bronchial epithelial cells, that oxidants cause the release of inflammatory mediators, such as IL-8, IL-1 and NO, and that these events are associated with increased expression of the genes for these inflammatory mediators and increased activation of NF-κB. NF-κB is highly expressed in CD4 + and CD8 + lymphocytes, macrophages, and monocytes in patients with COPD (Aldonyte et al., 2003) . In addition, NF-κB activation in lung tissue has been shown to correlate with lung functions (Crowther et al., 1999) suggesting that activation of NF-κB contributes to the pathogenesis of COPD. Indeed, oxidative stress seems to result in the upregulation of the genes for many inflammatory mediators, such as the cytokines IL-8, TNF-α, and NOsynthase via activation of NF-κB (Li & Verma, 2002) .
Myeloperoxidase
Myeloperoxidase (MPO) is a granulocyte proteolytic protein that is released from neutrophils during their activation. MPO in exhaled breath condensate has been shown to be elevated in patients with both asthma and COPD (Keatings & Barnes, 1997) . Recently, a positive relationship was observed between the concentration of MPO and the concentrations of 8-isoprostane and nitrite in exhaled breath condensate in patients with COPD (Romero et al., 2006) . In addition, the concentrations of eosinophil granule protein -eosinophil cationic protein (ECP), as well as the eosinophil granule-derived enzyme -eosinophil peroxidase (EPO), are increased both in asthma and COPD (Keatings & Barnes, 1997) . The onset of severe exacerbations of COPD is associated with further increases in COPD sputum neutrophil number and MPO levels (Tsoumakidou et al., 2005) .
Antioxidants
Lungs are unique because they have a large epithelial surface area that is at risk for oxidative stress-mediated injury. Oxidants are scavenged by enzymatic or nonenzymatic antioxidant defensive mechanisms. Antioxidant enzymes include the families of SODs, CAT and glutathione peroxidase (GPx). The non-enzymatic antioxidants include proteins such as albumin, ceruloplasmin and ferritin; and small molecules including reduced glutathione (GSH), bilirubin, ascorbic acid, α-tocopherol, β-carotene, lipoic acid, and uric acid. In the lung, intracellular antioxidants are expressed at relatively low levels and are not induced by oxidative stress, whereas the major antioxidants are extracellular (Comhair & Erzurum, 2002) .
Enzymatic antioxidants
The only enzymatic system decomposing superoxide radicals to hydrogen peroxide are SODs. There are three SODs: (i) intracellular copper-zinc SOD; (ii) mitochondrial manganese SOD; and (iii) extracellular SOD. Extracellular SOD has an important role in protecting matrix proteins of lungs against extracellular oxidants in the process of inflammation. Evidence is growing that oxidant production may be used by cells to signal an adaptive enzymatic antioxidant response to prevent oxidative stress. The expression of mitochondrial manganese SOD was significantly elevated in the resting leg muscles of COPD compared with healthy controls (Barreiro et al., 2003) . SODs as well as CAT and GPx are also present in the epithelial lining fluid. GSH is the principal small molecular-weight thiol in the lungs that is always in balance with its oxidised form (GSSG). Intracellularly GSSG is part of the glutathione redox system that uses GPx to detoxify lipid peroxidases and hydrogen peroxide. Glutathione is concentrated in the epithelial lining fluid in 100-fold higher amounts compared to plasma, 90% of which is in the reduced form (Comhair et al., 2000) . It has been demonstrated that in chronic smokers there is almost a doubling of glutathione in the epithelial lining fluid compared with non-smokers (Comhair et al., 2000) . There Fig. 2 . The effect of oxidants on intracellular glutathione (GSH) and nuclear factor-kappaB (NF-κB). Oxidants cause nuclear translocation of NF-κB, which upregulates genes for cytokines such as TNF-α and IL-8. These themselves can produce oxidative stress through the release of oxidants from mitochondria that may result in decreased intracellular GSH.
is a profound decrease in GSH resulting from an exposure to cigarette smoke (Fig. 2) . Recovery of GSH concentrations starts after 12 hours after smoking cessation, and by 24 hours there is a rebound increase in GSH (Comhair & Erzurum, 2002) .
Non-enzymatic antioxidants
Vitamin A (β-carotene) is a unique chain-breaking lipid-soluble antioxidant which traps the peroxyl radicals. Vitamin A also serves as a prohormone for retroretinoids and intersects with signal transduction at cytoplasmic and membrane sites (Agackiden et al., 2004) . Vitamin E (α-tocopherol) is lipophilic chainbreaking antioxidant present within lipoproteins and cell membranes. It plays a major role in maintaining cell membrane's integrity by limiting lipid peroxidation by ROS (Canbaz et al., 2003) and so suppresses the oxidative damage of the membranes (Lee et al., 2002) . Serum concentrations of vitamin A and vitamin E were significantly lower in patients with COPD compared to healthy subjects, and decreased further during COPD exacerbations (Tug et al., 2004) . Vitamin C (ascorbic acid) is a water-soluble, chain-breaking antioxidant, which scavenges aqueous superoxide radicals and has multiple antioxidant properties. Reductions in serum vitamin C concentrations were recently shown to be related to the severity of obstructive lung impairment in COPD (Ochs-Balcom, 2006) . This finding supports the hypothesis that the oxidant/antioxidant imbalance is associated with chronic airflow limitation.
Smoking-induced changes in antioxidant defence mechanisms in the lungs
A number of disturbances in antioxidant system have been observed in experimental models of cigarette smoke-induced lung injury as well as in smokers, and in patients with COPD. In general, tissues and cells respond to mild oxidative stress by increasing antioxidant defence mechanisms. However, high levels of ROS and RNS may overwhelm the capacity of antioxidant enzymes, resulting in oxidant-mediated injury or cell death (Comhair & Erzurum, 2002) . In smokers and in patients with COPD, elevated levels of GSH and GPx activity, and an induction of MnSOD have been observed in epithelial lining fluid (Comhair et al., 1999) . A question arises to what extent do the increases in local antioxidative systems protect the lungs against the cigarette smoke-induced damage. Human studies indicate that certain cigarette smokers, for genetic or other reasons, may respond by increasing their antioxidant enzymes, while others do not. Repine et al. (1997) suggest that if oxidative stress contributes to the development of COPD in smokers, then adaptive increases in antioxidants in the lungs may be protective against the lung injury. Importantly, high inter-individual variability in the adaptive increases in antioxidative enzymes in response to oxidative stress may explain why some cigarette smokers do, and some do not develop the disease.
Second-hand (passive) smoke, also known as environmental tobacco smoke, is a mixture of the smoke given off by the burning end of a cigarette and the smoke exhaled from the lungs of smokers. It is involuntarily inhaled by non-smokers and can cause or exacerbate a wide range of adverse health effects, including cancer, respiratory infections, and asthma (Diethelm et al., 2004) . Passive smoking with an exposure of more than 10 years has been associated with chronic bronchitis in non-smoking individuals (Piitulainen et al., 1998) . Recent studies indicate that analogically to active smoking, passive exposure to tobacco results in negative effects in the lungs through the generation of oxidative stress and/or reduction of antioxidant capacity (Murata et al., 2004; Iwai et al., 2005; Janssen et al., 2005; Lindberg et al., 2005; Schikowski et al., 2005; Sunyer, 2005) . Smoking cessation is the only treatment strategy against COPD that is proven to be effective in slowing down the disease progression (Ricciardolo et al., 2005) . The effects of smoking cessation on airway inflammation are unknown, although crosssectional studies suggest ongoing inflammation also in ex-smokers (Willemse et al., 2005) .
Smoking-induced changes in antioxidant defence mechanisms in the systemic circulation
Numerous studies have reported on increased levels of oxidants in association with reduced antioxidant capacity in circulating blood in smokers and in patients with COPD. This can be regarded as the evidence that oxidative stress spreads out to the circulation, and can therefore contribute to the pathogenesis of systemic effects of the disease (Barreiro et al., 2003; Eisner et al., 2005) .
In patients with COPD and in healthy smokers, significantly higher levels of oxidized GSH have been observed in erythrocytes compared to healthy nonsmokers (Mak et al., 2004) . Furthermore, Calikoglu et al. (2002) found significantly decreased levels of reduced GHS in erythrocytes of patients with acute ex-acerbations of COPD. In addition, Kurys et al. (2001) documented significant reductions of CAT, SOD and GPx activities in red blood cells of patients with COPD. Further studies are needed to explore the individual variability in the response of antioxidant enzymes in the systemic circulation to smoking-induced oxidative stress, and its role in oxidative-stress-induced lung injury.
Several studies have indicated that the antioxidant capacity of plasma is decreased in smokers and in patients with COPD, in association with increased markers of oxidative stress in the lungs, bronchoalveolar lavage fluid, and plasma (Comhair et al., 2000; Tug et al., 2004,) . Products of lipid peroxidation are increased also in plasma of smokers and of patients with COPD (Tkáčová et al., 2005; Kluchová et al., 2006) . During exacerbations of COPD, the antioxidant capacity of plasma is reduced further, and products of lipid peroxidation are increased even more than in stable COPD. In the course of treatment of the disease exacerbations, the oxidant/antioxidant imbalance in the blood returns towards baseline values (Rahman et al., 1997) .
Relationships between oxidative stress and pulmonary functions
Some of the markers of oxidative stress correlate with the degree of airflow limitation in patients with COPD, suggesting a pathogenetic role of oxidative stress in the deterioration in lung function in this disorder. Schunemann et al. (1997) were the first to report an inverse correlation between plasma lipid peroxidation products and lung functions. However, the studies on the relationships between oxidant/antioxidant imbalance and pulmonary functions did not yield consistent results. On one hand, we have shown that lipid peroxidation products correlate inversely with the severity of airflow limitation (Tkáčová et al., 2005; Kluchová et al., 2006) . In patients with moderate to severe COPD, the activity of GPx in erythrocytes and plasma MDA levels were related to the disease severity as assessed by FEV 1 : patients with severe COPD had the lowest activity of GPx, and the highest MDA levels (Kluchová et al., 2006) . On the other hand, however, Rahman et al. (2000) failed to document a significant relationship between spirometric data and antioxidant capacity of plasma or plasma protein thiols. Therefore, these authors suggested that antioxidant capacity in plasma would be unlikely related to measurements of airway obstruction, due to high within-individual variability in oxidative stress in plasma caused by smoking. There seems to be, however, less intra-individual variability in antioxidative enzymes measured in erythrocytes. Indeed, relationships between oxidative enzymatic systems and lung function impairment were seen in those previous reports studying the antioxidative enzymes in erythrocytes and not in plasma (Rahman et al., 2000) .
The effect of antioxidants on the progression of COPD
Unlike patients with asthma, those with COPD are less responsive to the anti-inflammatory actions of corticosteroids (Barnes & Adcock, 2004 , Kharitonov & Barnes, 2004 . Therefore several antioxidants have been investigated to improve lung function in patients with COPD, such as vitamins E or C (Canbaz et al., 2003) . Preliminary results have suggested that also NOS inhibitors and NO donors may have clinical benefits in COPD patients .
N-Acetyl cysteine (NAC), originally developed as a mucolytic agent, is a glutathione precursor with antioxidant properties. It has been observed that NAC is able to inhibit NF-κB (Zafarullah et al., 2003) . In addition, meta-analyses have documented a small but significant clinical benefit of NAC in reducing COPD exacerbations (Grandjean et al., 2000; Poole & Black, 2001 ). Nevertheless, a recent large, randomized, placebo-controlled, 3-year clinical trial did not indicate any significant effects of NAC at prevention of deterioration in lung function and prevention of exacerbations in patients with COPD (Decramer et al., 2005) . Therefore, further studies are needed to clarify the role of NAC in the treatment strategy of COPD.
Other potential therapeutic option to target oxidative stress in the lungs of patients with COPD is represented by inhibitors of iNOS that are capable to inhibit the formation of peroxynitrite. Selective, potent, and long-lasting inhibitors of iNOS are now in clinical development (Hansel et al., 2003) .
In the next few years, novel anti-inflammatory agents with potential antioxidative properties might become available for the treatment of COPD. The novel group of pharmacological compounds is represented by inhibitors of phosphodiesterase 4, such as roflumilast and cilomilast. Phosphodiesterase 4 inhibitors possess anti-inflammatory activity in vitro in a range of inflammatory cell types relevant to COPD and asthma (Lipworth, 2005) . In patients with moderate to severe COPD, long-term treatment with roflumilast improved FEV 1 and other lung function parameters and reduced the rate of mild exacerbations (Rabe et al., 2005) . Similarly, cilomilast maintained pulmonary function, improved health status, and reduced the rate of COPD exacerbations (Renard et al., 2006) . Whether these anti-inflammatory effects are associated with the impact on oxidative stress remains to be established in future studies.
Conclusion and future perspectives
In conclusion, there is now a large body of evidence to indicate that oxidative stress and inflammation are present both in the lungs and systemic circulation in smokers and in patients with stable COPD. These find-ings may explain high prevalence of systemic complications, such as cachexia, muscle wasting, osteoporosis and cardiovascular diseases among patients with COPD. Physiological insights into the pathogenesis of cigarette smoke-induced lung injury and COPD raise several intriguing questions. First, it remains to be determined which biomarkers will be reliable and clinically useful predictors of pulmonary function decline over time in smokers and in patients with COPD. Second, since oxidative stress may represent one of the key mechanisms in the development of clinical conditions associated with increased mortality in smokers and patients with COPD (i.e. the loss of pulmonary functions, cachexia, and cardiovascular diseases), the degree of oxidative stress might potentially gain a prognostic value in these patients. Third, further studies are needed to determine whether attenuation of the systemic inflammatory and oxidative processes can modify the risk of systemic complications in COPD.
